ClinicalTrials.gg
CompletedNCT05101317Updated Jan 21, 2026Results posted

A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain

A Phase 2 interventional study of HMI-115 and Placebo in Endometriosis, sponsored by Hope Medicine (Nanjing) Co., Ltd. Completed at 5 sites in 3 countries. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Hope Medicine (Nanjing) Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 169 studies in Endometriosis with a site in United States — 38 open to participants now, 48 under way, 5 of them phase 3. Endometriosis · United States.

Enrollment
26th of 131
142 · median 60
Started
2021
with 3 others
Phase 2
39 of 169
1 open now
Registered
113th of 169
by date

Among the 169 studies in Endometriosis with a site in United States, this one is the 26th largest by enrollment of the 131 interventional ones that give a count, is one of 4 that started in 2021, is one of 39 in phase 2, and was the 113th registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

38 of the 169 studies in Endometriosis with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 49 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 169 studies in Endometriosis with a site in United States, or all of them as a file.
02

Study summary

This study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.

Read the detailed description

This study aims to evaluate the safety and efficacy of HMI-115 versus a placebo in pre-menopausal women with moderate to severe Endometriosis associated pain.

The study will determine the safety and efficacy of HMI 115 at 3 dose levels.

03

Conditions studied

  • Endometriosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pre-menopausal female subjects, between 18 and 49 years of age, inclusive, at the time of signing .
  2. Subject must have a clinical diagnosis of endometriosis (laparoscopy or laparotomy) as documented by medical records within 10 years before screening.
  3. Subject must have a Composite Pelvic Signs and Symptoms Score total score of ≥ 6 with a score of at least 2 for DYS and at least 2 for NMPP at screening.
  4. Subject agrees not to participate in another interventional study while participating in the present study.

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant or breastfeeding or is planning a pregnancy during the study period.
  2. Subject has chronic pelvic pain that is not caused by endometriosis or has any other chronic pain syndrome or other chronic therapy, or that would interfere with the assessment of endometriosis-related pain
  3. Subject has gynecologic condition other than endometriosis
  4. Subject has previous history of a severe, life-threatening or other significant sensitivity to any opioids or non-steroidal anti inflammatory drugs (NSAIDS) or any to their use such as gastrointestinal ulcer or bleeding
  5. Subject has history of hysterectomy and/or bilateral oophorectomy
  6. Subjects with past or present pituitary tumor growth
  7. Subjects has a history of osteoporosis or other metabolic bone disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    HMI-115 60mg

    Once Every 2 weeks, subcutaneously injection

    Drug: HMI-115

  • Experimental
    HMI-115 120mg

    Once Every 2 weeks, subcutaneously injection

    Drug: HMI-115

  • Experimental
    HMI-115 240mg

    Once Every 2 weeks, subcutaneously injection

    Drug: HMI-115

  • Placebo comparator
    Placebo

    Once Every 2 weeks, subcutaneously injection

    Drug: Placebo

Interventions

  • HMI-115 is human monoclonal antibody

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 (Percentage Change)

    The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

    Time frame: Baseline, Week 12

  2. Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12(Absolute Score Change)

    The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale(NRS) From Baseline to Week 24 (Percentage Change)

    The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

    Time frame: Baseline, Week 24

  2. Change in Non-menstrual Pelvic Pain (NMPP) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 and 24 (Percentage Change)

    The Numeric Rating Scale for non-menstrual pelvic pain (NMPP) ranges 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

    Time frame: Baseline, week 12 and 24

  3. Change in Dyspareunia (DYSP) Measured by NRS From Baseline to Week 12 and 24 (Percentage Change)

    The Numering Rating Score for dyspareunia ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

    Time frame: Baseline, week 12 and 24

  4. Change From Baseline (CFB) in the Monthly Mean Endometriosis Daily Impact Pain Scale for DYS, NMPP and DYSP

    Endometriosis Daily Impact Pain Scale ranges from 0 (none) to 3 (severe) as recorded in a daily electronic diary. The higher scores mean worse outcome.

    Time frame: Baseline, week 12 and 24

  5. Change From Baseline (CFB) by Visit in Permitted Rescue Medication Use

    Assessment was based on average pill counts at each apecific period od days

    Time frame: Baseline, week 12 and 24

  6. Change in Menstrual Period Heaviness (Bleeding) From Baseline by Visit

    Assessment was based on tampons or pads used. 0 means no bleeding, 4 means heavy bleeding. Higher score means more bleeding.

    Time frame: Baseline, week 12 and 24

  7. Change in Dysmenorrhea(DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 24 (Absolute Score Change)

    The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

    Time frame: Baseline, Week 24

  8. Change in Non-menstrual Pelvic Pain (NMPP) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 and 24 (Absolute Score Change)

    The Numeric Rating Scale (NRS) for non-menstrual pelvic pain (NMPP) ranges 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

    Time frame: Baseline, Week12, Week24

  9. Change in Dyspareunia (DYSP) Measured by Numering Rating Score(NRS) From Baseline to Week 12 and 24 (Absolute Score Change)

    The Numering Rating Score(NRS) for dyspareunia(DYSP) ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

    Time frame: Baseline, Week12, Week24

07

Results

Posted Nov 18, 2025

Participant flow

The study was conducted in China, the United States of America (USA), and Poland.Total of 310 subjects were screened, of which 142 subjects were randomized. Among them, 36 subjects received HMI-115 60 mg, 36 received HMI-115 120 mg, 35 received HMI-115 240 mg, and 35 subjects were randomized to receive placebo. In the protocol version 5.0, part 2 of the study was deleted and not executed. So no subject was recruited in the former planned part 2 study.

Week1-13
Participant flow — Week1-13
MilestoneHMI-115 60mgHMI-115 120mgHMI-115 240mgPlacebo
Started36363535
Completed36333534
Not completed0301
Withdrew: Adverse event0100
Withdrew: Withdrawal by subject0200
Withdrew: Early withdrawl0001
Week 13-25
Participant flow — Week 13-25
MilestoneHMI-115 60mgHMI-115 120mgHMI-115 240mgPlacebo
Started36333534
Completed35303334
Not completed1320
Withdrew: Lost to follow-up0010
Withdrew: Withdrawal by subject1100
Withdrew: Patient decide to have oral contraception/refuse to come back0210

Outcome measures

PrimaryChange in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 (Percentage Change)

The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percentage of change from baseline
Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 (Percentage Change)
percentage of change from baselineHMI-115 60mgHMI-115 120mgHMI-115 240mgPlacebo
Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 (Percentage Change)-27.35 ± 9.568-34.72 ± 9.630-41.57 ± 10.234-18.61 ± 8.859
PrimaryChange in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12(Absolute Score Change)

The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12(Absolute Score Change)
score on a scaleHMI-115 60mgHMI-115 120mgHMI-115 240mgPlacebo
Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12(Absolute Score Change)-2.57 ± 0.542-3.29 ± 0.546-3.26 ± 0.579-2.31 ± 0.502
SecondaryChange in Dysmenorrhea (DYS) Measured by Numeric Rating Scale(NRS) From Baseline to Week 24 (Percentage Change)

The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage of change from baseline
Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale(NRS) From Baseline to Week 24 (Percentage Change)
percentage of change from baselineHMI-115 60mgHMI-115 120mgHMI-115 240mgPlacebo
Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale(NRS) From Baseline to Week 24 (Percentage Change)-6.86 ± 11.912-21.82 ± 12.039-14.07 ± 12.7363.97 ± 10.898
SecondaryChange in Non-menstrual Pelvic Pain (NMPP) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 and 24 (Percentage Change)

The Numeric Rating Scale for non-menstrual pelvic pain (NMPP) ranges 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

Time frame:
Baseline, week 12 and 24
Reported as:
Least squares mean · percentage of change from baseline
Change in Non-menstrual Pelvic Pain (NMPP) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 and 24 (Percentage Change)
percentage of change from baselineHMI-115 60mgHMI-115 120mgHMI-115 240mgPlacebo
Week12 %CFB-33.74 ± 10.283-47.48 ± 10.363-51.66 ± 11.157-27.61 ± 9.577
Week24 %CFB-11.22 ± 15.063-56.62 ± 15.252-38.05 ± 16.341-33.30 ± 13.800
SecondaryChange in Dyspareunia (DYSP) Measured by NRS From Baseline to Week 12 and 24 (Percentage Change)

The Numering Rating Score for dyspareunia ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

Time frame:
Baseline, week 12 and 24
Reported as:
Least squares mean · percentage of change from baseline
Change in Dyspareunia (DYSP) Measured by NRS From Baseline to Week 12 and 24 (Percentage Change)
percentage of change from baselineHMI-115 60mgHMI-115 120mgHMI-115 240mgPlacebo
Week12 %CFB-7.01 ± 19.073-38.43 ± 20.420-11.70 ± 22.342-24.98 ± 16.627
Week24 %CFB-2.32 ± 28.065-61.91 ± 30.0483.47 ± 30.259-13.17 ± 22.422
SecondaryChange From Baseline (CFB) in the Monthly Mean Endometriosis Daily Impact Pain Scale for DYS, NMPP and DYSP

Endometriosis Daily Impact Pain Scale ranges from 0 (none) to 3 (severe) as recorded in a daily electronic diary. The higher scores mean worse outcome.

Time frame:
Baseline, week 12 and 24
Reported as:
Least squares mean · score on a scale
Change From Baseline (CFB) in the Monthly Mean Endometriosis Daily Impact Pain Scale for DYS, NMPP and DYSP
score on a scaleHMI-115 60mgHMI-115 120mgHMI-115 240mgPlacebo
Week 12 DYS-0.83 ± 0.184-1.06 ± 0.185-1.13 ± 0.197-0.79 ± 0.172
Week 24 DYS-0.60 ± 0.192-0.87 ± 0.194-0.66 ± 0.205-0.48 ± 0.176
Week12 NMPP-0.49 ± 0.119-0.61 ± 0.119-0.69 ± 0.128-0.46 ± 0.110
Week24 NMPP-0.42 ± 0.162-0.78 ± 0.165-0.63 ± 0.178-0.49 ± 0.149
Week12 DYSP-0.01 ± 0.169-0.48 ± 0.173-0.16 ± 0.187-0.02 ± 0.149
Week24 DYSP-0.19 ± 0.210-0.69 ± 0.230-0.28 ± 0.222-0.13 ± 0.179
SecondaryChange From Baseline (CFB) by Visit in Permitted Rescue Medication Use

Assessment was based on average pill counts at each apecific period od days

Time frame:
Baseline, week 12 and 24
Reported as:
Mean · pill
Change From Baseline (CFB) by Visit in Permitted Rescue Medication Use
pillHMI-115 60mgHMI-115 120mgHMI-115 240mgPlacebo
CFB Week12 Average pill count Tier 1-0.656 ± 1.4020-0.463 ± 0.9113-1.001 ± 1.4900-0.384 ± 0.8579
CFB Week24 Average pill count Tier1-0.394 ± 1.4724-0.643 ± 1.8192-0.590 ± 1.1144-0.414 ± 0.9968
SecondaryChange in Menstrual Period Heaviness (Bleeding) From Baseline by Visit

Assessment was based on tampons or pads used. 0 means no bleeding, 4 means heavy bleeding. Higher score means more bleeding.

Time frame:
Baseline, week 12 and 24
Reported as:
Mean · score on a scale
Change in Menstrual Period Heaviness (Bleeding) From Baseline by Visit
score on a scaleHMI-115 60mgHMI-115 120mgHMI-115 240mgPlacebo
CFB Week 12 Average Score-0.415 ± 0.7062-0.571 ± 0.6114-0.363 ± 0.6437-0.197 ± 0.4525
CFB Week 24 Average score-0.119 ± 0.6463-0.390 ± 0.8419-0.585 ± 0.6965-0.114 ± 0.4920
SecondaryChange in Dysmenorrhea(DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 24 (Absolute Score Change)

The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change in Dysmenorrhea(DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 24 (Absolute Score Change)
score on a scaleHMI-115 60mgHMI-115 120mgHMI-115 240mgPlacebo
Change in Dysmenorrhea(DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 24 (Absolute Score Change)-1.87 ± 0.579-2.95 ± 0.585-2.18 ± 0.617-1.45 ± 0.529
SecondaryChange in Non-menstrual Pelvic Pain (NMPP) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 and 24 (Absolute Score Change)

The Numeric Rating Scale (NRS) for non-menstrual pelvic pain (NMPP) ranges 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

Time frame:
Baseline, Week12, Week24
Reported as:
Least squares mean · score on a scale
Change in Non-menstrual Pelvic Pain (NMPP) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 and 24 (Absolute Score Change)
score on a scaleHMI-115 60mgHMI-115 120mgHMI-115 240mgPlacebo
Week12-1.46 ± 0.344-1.64 ± 0.347-1.92 ± 0.373-1.36 ± 0.321
Week24-1.21 ± 0.452-2.07 ± 0.457-1.67 ± 0.490-1.26 ± 0.415
SecondaryChange in Dyspareunia (DYSP) Measured by Numering Rating Score(NRS) From Baseline to Week 12 and 24 (Absolute Score Change)

The Numering Rating Score(NRS) for dyspareunia(DYSP) ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

Time frame:
Baseline, Week12, Week24
Reported as:
Least squares mean · score on a scale
Change in Dyspareunia (DYSP) Measured by Numering Rating Score(NRS) From Baseline to Week 12 and 24 (Absolute Score Change)
score on a scaleHMI-115 60mgHMI-115 120mgHMI-115 240mgPlacebo
Week12-0.23 ± 0.487-1.33 ± 0.489-0.90 ± 0.518-0.54 ± 0.423
Week 24-1.03 ± 0.547-2.13 ± 0.591-1.57 ± 0.546-0.68 ± 0.456

Adverse events

Collected over All AEs and SAEs will be collected from the signing of informed consent form until the end of study participation (About 34 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HMI-115 60mg0/27 (0%)0/27 (0%)15/27 (55.6%)
HMI-115 120mg0/27 (0%)0/27 (0%)16/27 (59.3%)
HMI-115 240mg0/24 (0%)1/24 (4.2%)18/24 (75%)
Placebo0/30 (0%)0/30 (0%)11/30 (36.7%)
Most frequent serious events
Most frequent serious events
EventHMI-115 60mgHMI-115 120mgHMI-115 240mgPlacebo
Breast massReproductive system and breast disorders0/270/271/240/30
Most frequent other events
Showing 10 of 15
Most frequent other events
EventHMI-115 60mgHMI-115 120mgHMI-115 240mgPlacebo
HeadacheNervous system disorders1/271/274/240/30
DizzinessNervous system disorders1/271/271/244/30
Injection site pruritusGeneral disorders1/272/273/241/30
AmenorrhoeaReproductive system and breast disorders1/270/273/240/30
Injection site rashGeneral disorders2/273/271/240/30
NasopharyngitisInfections and infestations1/273/272/241/30
PyrexiaGeneral disorders1/270/271/243/30
Ovarian cystReproductive system and breast disorders0/270/271/243/30
NauseaGastrointestinal disorders1/271/272/243/30
Injection site reactionGeneral disorders1/272/272/240/30

Baseline characteristics

PAS:All subjects in the FAS(All randomized subjects who take at least one dose of IMP) who have surgical diagnosis.

Age, Continuous
Age, Continuous(years)HMI-115 60mgHMI-115 120mgHMI-115 240mgPlaceboTotal
Mean39.9 ± 4.4336.4 ± 4.9937.4 ± 5.3138.1 ± 5.1738.0 ± 5.05
Sex: Female, Male
Sex: Female, Male(Participants)HMI-115 60mgHMI-115 120mgHMI-115 240mgPlaceboTotal
Female27272430108
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HMI-115 60mgHMI-115 120mgHMI-115 240mgPlaceboTotal
Hispanic or Latino10012
Not Hispanic or Latino26272429106
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HMI-115 60mgHMI-115 120mgHMI-115 240mgPlaceboTotal
American Indian or Alaska Native00000
Asian121391549
Native Hawaiian or Other Pacific Islander00000
Black or African American00101
White1514141558
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)HMI-115 60mgHMI-115 120mgHMI-115 240mgPlaceboTotal
United States11125
China121391549
Poland1413141354
Endometriosis duration
Endometriosis duration(months)HMI-115 60mgHMI-115 120mgHMI-115 240mgPlaceboTotal
Mean67.2 ± 37.857.0 ± 31.867.4 ± 28.773.7 ± 27.266.5 ± 31.7
BMI
BMI(kg/m2)HMI-115 60mgHMI-115 120mgHMI-115 240mgPlaceboTotal
Mean23.57 ± 4.01123.17 ± 3.22024.40 ± 4.04623.25 ± 4.22323.57 ± 3.873
DYS NRS
DYS NRS(units on a scale)HMI-115 60mgHMI-115 120mgHMI-115 240mgPlaceboTotal
Mean6.288 ± 1.42616.393 ± 2.11235.910 ± 1.82365.696 ± 2.00056.127 ± 1.7909

4 further baseline measures are reported on the registry.

08

Study locations

5 sites
  • Physicians' Research Options, LLC- Corner Canyon Clinic
    Draper, Utah 84020, United States
  • Tidewater Clinical Research/TPW
    Norfolk, Virginia 23502, United States
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100703, China
  • Instytut Matki i Dziecka
    Warsaw, Masovian Voivodeship, Poland
  • Specjalistyczna Poradnia Ginekologiczna Gabinet Ginekologiczny Dr med. Janusza Tomaszewskiego
    Bialystok, Podlaskie Voivodeship, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Sep 2024, 35 months.

Results were first posted in Nov 2025, 1 year 1 month after primary completion.

Of 44 phase 2 interventional studies under Endometriosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 37. This study's 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2021
First posted
Nov 1, 2021
StartActual
Oct 11, 2021
Primary completionActual
Sep 26, 2024
CompletionActual
Mar 19, 2025
Results first posted
Nov 18, 2025
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05101317
Lead sponsor
Hope Medicine (Nanjing) Co., Ltd
Responsible party
Sponsor
First posted
Nov 1, 2021
Start date
Oct 11, 2021
Primary completion
Sep 26, 2024
Completion
Mar 19, 2025
Results posted
Nov 18, 2025
Last update
Jan 21, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HMI-115

Start the discussion